Visit the Maricann Group Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Maricann Group Inc. Signs Definitive Agreement with Lovell Drugs for Medical Cannabis Retail Pharmacy Initiative
First Prescription Fulfilled on December 1st, 2017
TORONTO, ONTARIO–(Marketwired – Dec. 12, 2017) –
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) “Maricann” or the “Company”) is pleased to announce that it has entered into a definitive agreement with Lovell Drugs Limited (“Lovell Drugs”), Ontario’s oldest pharmacy chain, to be the exclusive provider of medical cannabis to its pharmacies.
Lovell Drugs will, in partnership with Maricann, implement a medical cannabis education and access program for its pharmacists and allied community physicians that facilitates the counselling and fulfillment of medical cannabis to its patients. Maricann will fulfill prescriptions directly to Lovell Drugs’ patients through the existing Access to Cannabis for Medicinal Purposes Regulations. Lovell Drugs has already commenced distribution of Maricann cannabis products to its patients, with the first prescription registered and fulfilled on December 1st, 2017.
Lovell Drugs is a well established resource for community physicians and ideally positioned to educate and counsel patients on medical cannabis to help ensure appropriate access, education and clinical oversight.
Pharmacists’ expert understanding of polypharmacy equips them as the standard of care for all patients. We believe that our medical cannabis initiative to distribute cannabis directly to patients, with pharmacists as their primary source of counselling and information is the better way. Until pharmacists are permitted to distribute cannabis products to patients directly, as is the case with all other pharmaceuticals, we believe this distribution model will provide an effective interim solution.
Ben Ward, CEO of Maricann
Lovell Drugs’ pharmacists are trusted health care professionals, providing services such as Clinic Days, MedsChecks, blood pressure tests, cannabis education counselling and information sessions for their patients.
The term of the agreement is four years, with an option to extend another three years if the parties mutually agree. Pursuant to the terms of the agreement Lovell Drugs will receive a percentage of Maricann product sale revenue generated from patients acquired and serviced from Lovell Drugs’ retail pharmacies. As part of the development of medical cannabis content Maricann has agreed to provide funding of up to $15,000 for initiatives to support continuing education for Lovell Drugs personnel and their patients.
Signing the definitive agreement with Lovell Drugs builds on Maricann’s deepening relationships with pharmacies across Canada in its similar education and distribution joint initiatives, elevating the standard of care for patients through the most trusted professionals in North America, pharmacists.
For more information about Maricann, please visit our website at www.maricann.com
The most reliable, fact-based information on Maricann Group found only on its Investor Dashboard.
Before this cannabis stock news is here, it's published to subscribers on 420 Investor.